Twist Bioscience Corporation (TWST) reported fiscal fourth-quarter results on November 12, 2026, and a wave of analysts promptly reset their targets. The seven most recent, verifiable post-earnings targets reviewed here are: Leerink Partners at $175, Guggenheim at $150, Canaccord Genuity at $150, TD Cowen at $137, Baird at $135, Barclays at $130, and UBS at $120. Their arithmetic mean is approximately $142, which rounds to a central target of $140.
The range among these current targets is wide — $120 to $175 — and older standing targets extend it further. A BWS Financial "Sell" rating with a $45 target, initiated in September 2026, remains well below the current price and illustrates how divided the Street is on valuation. Most covering analysts retain Buy or Outperform ratings, while UBS is Neutral, citing a higher bar given the company's premium valuation. Rather than a single consensus, the picture is one of a bullish majority wrestling with a stock that has already priced in substantial optimism. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.
Twist Bioscience Corporation (TWST) shares closed near $105 in mid-November 2026, down from an October 6 52-week high of $219.71 and above a 52-week low of $24.41. Reaching $140 would require about a 33% advance — a substantial move, not a marginal one. The stock remains up more than 200% year to date despite the pullback, underscoring how much AI-driven enthusiasm has already been embedded in the price.
The path toward the target would likely depend on the company demonstrating that its AI-enabled drug discovery and synthetic DNA businesses can sustain revenue growth while narrowing losses. Fiscal 2026 revenue rose about 22% to roughly $459 million, and the fiscal fourth-quarter net loss narrowed. However, management's fiscal 2027 outlook flagged a sharp slowdown in AI drug discovery growth, which triggered the post-earnings selloff and the target cuts.
Twist's differentiated silicon-based DNA synthesis platform gives it a cost and scale advantage in synthetic biology, and the company has been expanding its footprint in next-generation sequencing (NGS) tools and biopharma. Double-digit revenue growth, a narrowing net loss, and progress toward adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization) breakeven are genuine tailwinds. Renewed AI-driven demand for DNA synthesis, a broader life sciences tools recovery, and additional analyst target increases would all support a move back toward $140.
The principal obstacle is valuation. Twist is not yet GAAP (generally accepted accounting principles) profitable, trades at a premium price-to-book multiple of roughly 7.8, and carries a market capitalization near $7 billion. If AI drug discovery revenue decelerates faster than expected, or if losses persist longer than modeled, the stock's premium multiple could compress. Insider selling activity and competition in DNA synthesis add further downside risk, and a sector rotation away from high-multiple growth names would weigh on the shares regardless of company-specific fundamentals.
The shares now trade below their 20-day and 60-day moving averages, which sat near $137 and $148 respectively in mid-November, and well below the October high of $219.71. The $100 level has acted as near-term support during the post-earnings decline. To reach $140, the stock would first need to reclaim the $130-to-$150 zone, where the recent analyst targets and the moving averages cluster — a region that now also represents a meaningful resistance band. From what I see, monitoring these levels closely helps frame the risk-reward setup.
Analyst price targets generally reflect a roughly 12-month research horizon, though individual firms vary. The next earnings report, expected around early February 2027, is the key near-term catalyst, along with any updates to fiscal 2027 guidance on AI drug discovery growth and profitability. Investors should also watch analyst revisions, broader life sciences tools demand, interest-rate expectations, and any signs of renewed insider selling or capital-raising activity. I’m watching this closely as the next few quarters unfold.
I’ve found Tickeron’s AI Daily Buy/Sell Signals to be a practical addition to my routine. The tool uses artificial intelligence to monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on market conditions and technical behavior. For a name like Twist Bioscience Corporation (TWST), it offers a systematic way to cut through volatility and sentiment noise when tracking potential shifts in trend.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
TWST saw its Moving Average Convergence Divergence Histogram (MACD) turn negative on November 02, 2026. This is a bearish signal that suggests the stock could decline going forward. Tickeron's A.I.dvisor looked at 44 instances where the indicator turned negative. In 42 of the 44 cases the stock moved lower in the days that followed. This puts the odds of a downward move at 90%.
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on TWST as a result. In 61 of 76 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 80%.
TWST moved below its 50-day moving average on October 30, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for TWST crossed bearishly below the 50-day moving average on October 20, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 12 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 86%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TWST declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
TWST broke above its upper Bollinger Band on October 28, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for TWST entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a +10.77% 3-day Advance, the price is estimated to grow further. Considering data from situations where TWST advanced for three days, in 235 of 291 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
The Tickeron Valuation Rating of 5 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (17.967) is normal, around the industry mean (3.592). P/E Ratio (-54.166) is within average values for comparable stocks, (-1.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (131.305) among similar stocks. P/S Ratio (20.243) is also within normal values, averaging (442.120).
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. TWST’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 45 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 86 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron SMR rating for this company is 97 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TWST’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
a developer of proprietary semiconductor-based synthetic DNA manufacturing process
Industry Biotechnology